96 results about "Human influenza" patented technology

Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

Provided are compounds of Formula I,as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.

The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable of neutralising said human influenza virus strain. Whereas the prior art used known non-pathogenic avian strains to generate antibodies in humans against known pathogenic avian strains, the invention uses known pathogenic avian strains to protect against emerging pathogenic human strains. Furthermore, whereas the prior art focused on achieving a close antigenic match between the vaccine strain and the target strain, the invention selects vaccine strains based on their pathogenicity, regardless of any perceived close antigenic relationship to the target strain. As the invention does not require detailed knowledge of an emerging strain, a vaccine can be provided further in advance to reduce the risk and potential effects of a human pandemic outbreak.

The invention relates to a method for restraining enveloped virus infection, relative polypeptide and protein drug, belonging to biological medicine technical field. The invention comprises a method for restraining influenza virus, particularly for restraining highly pathogenic influenza virus and human influenza virus (as H1N1 hypotype and H3N2 hypotype), relative polypeptide and protein, relative nucleic acid encoding the polypeptide and protein, and relative carriers and cells for representing the polypeptide and protein.

The invention discloses a method and a kit for performing quick co-detection on anti-human Hi (Haemophilus influenzae) IgM (Immunoglobulin M) and IgG (Immunoglobulin G) antibodies based on magnetic separation and multi-color quantum dot labeling. The kit consists of anti-human Hi antibody capturing nano magnetic beads with an anti-human Hi IgM and IgG antibody gathering function, anti-human IgM and IgG antibody nano probes labeled by multi-color quantum dots, quality control substances and a PBST buffering solution, wherein the quality control substances comprise a positive quality control substance and a negative quality control substance; the positive quality control substance is serum, in which anti-human Hi IgM and IgG antibodies of human Hi infected people are respectively positive; the negative quality control substance is serum, in which anti-human Hi IgM and IgG are respectively negative. The kit and the method have the advantages of simplicity, quickness and high sensitivity, and can be used for carrying out synchronous detection on the anti-human Hi IgM and IgG antibodies.

The invention relates to polypeptide, protein or peptide-like medicine from influenza virus hemagglutinin, and a method of the polypeptide, belongs to the technical field of biological medicines, and in particular relates to eight influenza virus hemagglutinin fragment peptides which can block influenza virus infection and have the serial numbers SEQ ID NO.1 to SEQ ID NO.8. The fragment peptides can inhibit and block infection of different species and influenza viruses of different subtypes to a host, including multiple influenza virus strains such as highly pathogenic avian influenza virus, seasonal human influenza virus and the like. The invention provides the peptide sequence (including amino acid sequences of peptides and polynucleotide sequences of encoded peptides), derivative peptides (including amino acid sequences of peptides and polynucleotide sequences of encoded peptides), peptide compositions and independent or united applications of peptides in preventing or treating influenza virus, such as medicine combination of peptides provided by the invention and other anti-influenza medicines.

The invention relates to a fluorescent quantitative detection kit for simultaneously detecting human influenza A virus, human influenza B virus and novel coronavirus, and belongs to the technical field of nucleic acid detection. The detection kit specifically comprises four groups of specific primer pairs and probes, a negative quality control material, a positive quality control material and a fluorescent quantitative PCR reaction system, wherein the four groups of specific primer pairs and probes are respectively a pair of specific primers and a probe for detecting influenza A virus and influenza B virus, and two pairs of specific primers and two probes for detecting novel coronavirus; wherein the positive quality control material is an artificially synthesized target sequence, and the negative quality control material is deionized water; wherein the fluorescent quantitative PCR reaction system is composed of components for PCR reaction and reaction conditions. According to the kit disclosed by the invention, the specific primer pair and the probe are designed at a conservative site of a virus sequence; the kit can realize simultaneous detection of influenza A virus, influenza Bvirus and novel coronavirus in a single tube, has strong detection specificity and high sensitivity, and can accurately and rapidly distinguish influenza from new coronapneumonia patients from people,so as to realize early discovery, early isolation and early treatment. The kit has important application value in the fields of disease monitoring, clinical diagnosis and the like.

The invention provides a novel severe acute respiratory syndrome coronavirus 2 N proteantigen variant and an application thereof to detection of the novel severe acute respiratory syndrome coronavirus2 antibody, and relates to variants of N protein important epitope polypeptide. The variants reduce the non-specific reaction of the novel severe acute respiratory syndrome coronavirus 2 protein as acapture antigen with other coronavirus antibodies such as SARS and human influenza coronavirus antibodies. The polypeptide has coronavirus N protein epitope peptide activity, and cysteine residues are added to the C end of the polypeptide. Amino acid residue sites of the mutation are selected from: lysine at the 342rd site, lysine at the 347 site, lysine at the 387 site and lysine atthe 388 site are mutated into amino acids with relatively low homology. The sequence of the N protein 340-419 polypeptide is shown as SEQ ID NO 7. The invention further discloses an antigen composition, use and method of the variant.

Recombinant PB2 tryptophan variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such viruses and methods for the prophylactic treatment of influenza in humans.

The invention provides a special detection tool capable of screening susceptible population of bird influenza and human influenza viruses. The detection tool is a lectin testing chip aiming at a saliva sample and adopts an epoxidation film base; two types of lectins including MAL-II (Maackia Amurensis Leukoagglutinin-II) and SNA (Sambucus Nigra Agglutinin) are fixed on the epoxidation film base by sample application. A corresponding lectin chip kit comprises the lectin testing chip, confining liquid, washing liquid and an incubation buffer solution. The invention further optimizes a preparation and treatment method of the lectin testing chip so as to establish an optimal reaction system for detecting saliva glycoprotein carbohydrate chain end sialic acid alpha2-3 and alpha2-6 carbohydrate chain structures in the saliva sample. The product provided by the invention is low in production cost and strong in testing pertinence; the inherent advantages of the lectin chip are combined to rapidly, simply and efficiently detect information of an evaluating result of the susceptible population of the bird influenza and human influenza viruses without damages.

The invention discloses a method and test strip for rapidly detecting people susceptible to avian flu and human influenza. The test strip orderly comprises a sample pad, a gold labeled pad, a detection control zone and a water absorption pad for absorbing the excess liquid in a detected sample along a chromatography direction. The detection control zone orderly comprises a detection band and a quality control line. The gold labeled pad comprises colloidal gold labeled lectin MAL-II or SNA. The detection band comprises stable internal reference lectin which is not bonded to the lectin MAL-II or a stable internal reference lectin which is not bonded to the lectin SNA. One end of the sample pad of the test strip is inserted into a saliva sample or is contained by the oral cavity, after 10 to 15 minutes, the test strip is taken out and the color development states of the detection band and the quality control line are observed so that the detection result is obtained. The method and test strip realize non-invasive, safe and simple detection of people susceptible to avian flu and human influenza.

The invention provides antibody reagents for screening for seed viruses, in particular, antibodies that bind to one or more discontinuous epitopes in hemagglutinin (HA) polypeptide of human influenza virus (H1N1 strain). Additionally, the invention relates to compositions, kits, supports, and biologicals comprising the antibodies or fragments thereof. Also provided are nucleic acids encoding such antibodies or fragments, including, cells and / or hybridomas which generate such molecules. Additional embodiments relate to the immunogens useful in generating the antibodies, including nucleic acids encoding such immunogens, and compositions comprising such immunogens. Further embodiments relate to methods for screening for seed viruses, including human influenza type A virus seed viruses, using the antibodies or fragments thereof. Embodiments of the invention also provide for the prevention, reduction of incidence of, or therapy of subjects having influenza, via administration of the seed viruses, or vaccines and / or pharmaceutical compositions containing the seed viruses.

The invention relates to an immune agonist containing element selenium for improving the immune function, in particular to a purine compound 8-substituted derivative. The immune agonist containing selenium element of the invention is a compound showed in formula (1). Owing to the immune-competence of the selenium element, the immune agonist containing selenium element of the invention leads to stronger immune improving activity of the compound than the corresponding compound analog (the representative compound 9) of the invention, which is applied in resisting viral diseases such as Hepatitis B Virus and Hepatitis C Virus, AIDS, SARS, human influenza and bird flu, and the treatment and assistance of various cancers, with good efficacy.

The invention discloses a combined vaccine of seasonal influenza and pandemic influenza for people. The hemagglutinin concentration of each vaccine is 10-60 mug / ml of H1N1 human influenza vaccine,10-60 mug / ml of H3N2 human influenza vaccine, 10-60 mug / ml of B human influenza vaccine, and 10-60 mug / ml of H5N1 human influenza vaccine respectively. The invention also discloses a preparation method of the combined vaccine. The combined vaccine disclosed by the invention has high safety; the problem that the traditional avian influenza vaccine is difficultly vaccinated at a large scale is solved; explosive epidemics of the H5N1 human influenza vaccine is effectively prevented and controlled when the seasonal influenza is prevented; the combined vaccine has great social and economic benefits.

The invention relates to a conjugate of virus-like particles (VLP) of oligopeptide vector Q[beta] bacteriophage with target immunotherapy and conservative peptides M2e of human influenza virus M2 protein. The conjugate is mainly used for preventing human influenza A. The conjugate is coupled by a Sulfo-SMCC method which comprises a first step of preparing the virus-like particles (VLP) of the Q[beta] bacteriophage; a second step of preparing the virus-like particles (VLP) activated by Sulfo-SMCC; and a third step of preparing the conjugate of M2e-VLP. The conjugate can produce high titer protective antibody in mice and cross-protect the attack of various subtypes of the influenza A viruses.

The present invention relates to a method for detecting an avian influenza virus by an immunological assay using an anti-influenza virus antibody being unreactive to human influenza type-A virus subtypes H1, H2 and H3 and a human influenza type-B virus and being reactive to plural subtypes of avian influenza viruses, and an immunochromatographic test tool for use in the method. According to the present invention, an avian influenza virus can be detected specifically, rapidly and in a simple manner, as distinguishing an avian influenza virus from a human influenza virus.

The invention relates to a reconstruction influenza A H1N1 virus inactivated vaccine strain. The reconstruction influenza A H1N1 virus inactivated vaccine strain is characterized by expressing HA protein and NA protein of the influenza A H1N1 virus. In particular, the reconstruction influenza A H1N1 virus inactivated vaccine strain is SC / PR8. The invention further discloses a method for preparing the reconstruction influenza A H1N1 virus inactivated vaccine strain (SC / PR8), and a use of the reconstruction influenza A H1N1 virus inactivated vaccine strain (SC / PR8) in prevention of animal influenza A H1N1 or human influenza A H1N1.

The invention provides a quadrivalence combined vaccine comprising H1N1, H3N2, B types flu and H5N1 type avian influenza and a preparing method. Concentration of each vaccine hemagglutinin is calculated with hemagglutinin: H1N1 type flu vaccine 20-40 mcg / mL, H3N2 type flu vaccine 20-40 mcg / mL, B type flu vaccine 20-40 mcg / mL and H5N1 type flu avian influenza 20-40 mcg / mL. The vaccine combining with human flu and avian influenza for human can solves problem of difficult to vaccination avian influenza vaccine, prevents avian influenza at the same time prevents huamn flu. Four indications (egg albumen, endotoxin, total protein contents, rate of total protein and hemagglutinin) The combined vaccine closly-related with side effect in the combined vaccine has low flu preparing regulation than national regulation, and has higher safety.

The invention discloses buccal tablets for preventing influenza virus and application of the buccal tablets. The buccal tablets comprise glycoprotein of a SAalpha2-3Gal sugar chain structure and glycoprotein of a SAalpha2-6Gal sugar chain structure. According to the technical scheme, the buccal tablets have the advantages of directly acting on the mouth cavity and the throat, increasing the concentration of glycoprotein of the SAalpha2-3Gal sugar chain structure and the SAalpha2-6Gal sugar chain structure, neutralizing and inhibiting recognition of avian and human influenza virus on the human body upper respiratory tract cell surface specific receptor, and achieving the effect of preventing avian and human influenza virus infection; due to slow mouth dissolving, medicine can stay on the surface of the mouth cavity and the throat for a long time, and the medicine effect is continuously achieved.

The present invention provides a novel human compound interferon spray for preventing and curing various types of influenza virus infection and its production preparation method. The described human compound interferon spray composition includes various types of human interferon alpha or beta or gamma or omega or delta or epsi or kappa or lambda etc. human interleukin-2, natural polysaccharide, human alhumin and preservative substance. The described influenza virus includes human influenza virus and avian influenza virus type A and type B. The invented human compound interferon spray can obtain obvious effect for preventing and curing various types of influenza virus infection.

The invention discloses a method and a kit for human influenza virus typing detection based on magnetic resolution and colorful quantum dot labelling. The kit comprises anti-human influenza virus immune nano-magnetic beads, anti-human influenza virus nanoprobes, quality control samples, a sample treating liquid and a PBST buffer solution, wherein the anti-human influenza virus immune nano-magnetic beads are rich in human influenza virus antigen; the anti-human influenza virus nanoprobes are labelled by colorful quantum dots; the quality control samples are a positive quality control sample and a negative quality control sample; the positive quality control sample is obtained by drying an inactived A-type human influenza virus and an inactived B-type human influenza virus, and combining the dried human influenza viruses on a swab; the negative quality control sample is a pharynx swab of a person whose detection results for the A-type human influenza virus and the B-type human influenza virus are both negative through clinical confirmation. The method and the kit are simple, convenient, fast, and high in sensitivity. The invention further provides a preparation method and a use method of the kit.

The invention relates to a virus split deactivation method for a human influenza virus split vaccine, and belongs to the field of biological pharmacy. A method of firstly purifying and cracking H1N1 type, H3N2 type or B type monovalent influenza totivirus after gradient density centrifugal purification and then deactivating is adopted, so that the virus cracking effect can be improved, the deactivation time can be shortened, the deactivation efficiency can be increased, the using amount of a deactivator can be obviously reduced, deactivation operation steps can be simplified, the contamination risk can be reduced, factory buildings, facilities and energy consumption required for deactivation can be reduced, and the uniformity and the stability of deactivation can be increased.

The presently disclosed subject matter provides a novel approach for the treatment, prevention, and diagnosis of Cap-Snatching virus infections, particularly all classes of human influenza, including pandemic influenza. The methods involve the use of constructs for RNA-interference (RNAi).